NCT03221426 2026-03-09
KEYNOTE-585
Merck Sharp & Dohme LLC
Phase 3 Completed
Clinical Trials
47 trialsNCT04430738 2026-02-24
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Phase 2 Active not recruiting
NCT05567835 2026-02-23
TOGAR
Baylor College of Medicine
Phase 2 Terminated
NCT03504397 2026-02-13
Spotlight
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT03653507 2026-02-06
GLOW
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT04661150 2026-01-30
A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT01191697 2025-11-03
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT04363801 2025-10-09
DisTinGuish
Leap Therapeutics, Inc.
Phase 2 Terminated
NCT02872116 2025-08-07
CheckMate649
Bristol-Myers Squibb
Phase 3 Completed
NCT02730546 2025-06-22
Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery
Mayo Clinic
Phase 1/2 Completed
NCT03382600 2024-06-11
KEYNOTE-659
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT03283761 2024-02-06
FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma
Big Ten Cancer Research Consortium
Phase 2 Completed
NCT03472365 2024-01-11
A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT01515748 2023-12-13
PRODIGY
Sanofi
Phase 3 Completed
NCT02954536 2023-03-16
Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01212822 2022-09-07
Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer
Fox Chase Cancer Center
Phase 2 Completed
NCT01896531 2022-03-02
A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
Genentech, Inc.
Phase 2 Completed
NCT02322593 2021-12-20
SOLAR
Taiho Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT01928290 2020-08-25
FOLFIRINOX
Washington University School of Medicine
Phase 2 Completed
NCT02545504 2020-05-26
GAMMA-1
Gilead Sciences
Phase 3 Completed
NCT01913639 2020-05-15
FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00525785 2020-02-10
Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01747551 2020-02-10
FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00446290 2020-01-18
Study of Docetaxel, Capecitabine and Oxaliplatin in Advanced Stomach Cancer
Asan Medical Center
Phase 1 Completed
NCT00398398 2020-01-07
Study of XELOX With Cetuximab in Advanced Gastric Cancer
Asan Medical Center
Phase 2 Completed
NCT01498289 2019-11-07
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT00217581 2019-03-26
Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT00711243 2019-02-26
Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor
Northwestern University
Phase 1/2 Completed
NCT02358863 2018-09-06
mEGA
Georgetown University
Phase NA Terminated
NCT00354224 2018-07-16
Capecitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Stomach Cancer
Medical University of South Carolina
Phase 2 Terminated
NCT00938470 2018-03-29
Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT02359058 2018-01-24
A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer
Eli Lilly and Company
Phase 1 Completed
NCT01178944 2017-12-13
Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer
Roswell Park Cancer Institute
Phase 2 Completed
NCT00448682 2017-02-07
Combination Chemotherapy as First-Line Therapy in Treating Patients With Stage IV Gastric Cancer That Cannot Be Removed By Surgery
University of Miami
Phase 2 Terminated
NCT00526110 2016-10-31
Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00454636 2016-09-29
A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer.
Hoffmann-La Roche
Phase 2 Completed
NCT00982592 2016-01-25
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00515216 2016-01-07
Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors
Vanderbilt University
Phase 2 Completed
NCT01130337 2015-10-01
A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT00084617 2015-05-01
Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00447330 2015-02-13
XAGastric
Duke University
Phase 2 Completed
NCT00673673 2015-02-04
FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer
Yale University
Phase 2 Completed
NCT01246960 2014-10-08
A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00555620 2013-01-14
Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer
Pfizer
Phase 1 Completed
NCT00382720 2013-01-07
Docetaxel and Oxaliplatin in Gastric Cancer
Sanofi
Phase 2 Completed
NCT00514020 2012-11-01
Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Completed
NCT00335959 2012-08-17
S0425 Oxaliplatin, Capecitabine, and RT in Treating Patients W/Stomach Cancer That Can Be Removed By Surgery
SWOG Cancer Research Network
Phase 2 Terminated